Form 4: Cormorant Asset Management Reports Changes in BioAge Labs Ownership After IPO

Cormorant Asset Management and related entities report conversion of preferred stock and purchase of common stock in BioAge Labs following its initial public offering.

Summary

• Cormorant Asset Management, LP, along with related entities including Cormorant Private Healthcare Fund IV LP, Cormorant Private Healthcare Fund V LP, and Bihua Chen, filed a Form 4 detailing changes in beneficial ownership of BioAge Labs, Inc. (BIOA) stock.
• The filing reports transactions occurring on September 27, 2024, including the conversion of Series D Redeemable Convertible Preferred Stock into Common Stock upon the closing of BioAge Labs' IPO.
• A total of 5,263,772 shares of Series D Preferred Stock were converted into 1,179,529 shares of Common Stock.
• Additionally, 450,000 shares of Common Stock were purchased at a price of $18 per share.
• After these transactions, Cormorant Asset Management and related entities beneficially own 1,629,529 shares of Common Stock.
• Bihua Chen serves as the manager of Cormorant Asset Management, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP IV, LLC, and Cormorant Private Healthcare GP V, LLC.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The conversion of preferred stock to common stock is a standard procedure following an IPO, and the additional purchase of shares indicates continued confidence in the company. However, the filing itself is simply a reporting requirement and doesn't necessarily indicate a strong positive or negative outlook.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of BioAge Labs following its IPO.
• The purchase of additional common stock at $18 per share demonstrates continued investment in BioAge Labs by Cormorant Asset Management.

Management Comments

• Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders, providing transparency to the market regarding their investment activities in publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are a regulatory requirement for individuals and entities holding more than 10% of a company's shares, or who are officers or directors, similar to filings made by entities like Baker Bros. Advisors or FMR LLC when they adjust their holdings in other biotech companies.
• The conversion of preferred stock to common stock upon an IPO is a common practice, aligning with the terms outlined in the preferred stock agreements, similar to what was seen with the IPOs of companies like Moderna or BioNTech.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a slight dilutive effect on existing common shareholders.
• The purchase of additional shares by Cormorant Asset Management could be viewed positively by the market, potentially increasing investor confidence.

Key Dates